Clinical Trial

Target Therapy With GEMOX in Recectable Gallbladder Carcinoma Patients Monitored by ctDNA

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated October 16, 2024 (before its estimated June 2025 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this study is to evaluate the feasibility, efficacy and safety of target therapy according to genomic and proteomic profiling combined with GEMOX in recectable gallbladder carcinoma patients monitored by ctDNA.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2019-12-02; most recent amendment 2024-10-13.
Trial Details
NCT Number NCT04183712
Lead Sponsor Shanghai Jiao Tong University School of Medicine
Collaborators: Shanghai Zhongshan Hospital, Ruijin Hospital, RenJi Hospital, Qilu Hospital of Shandong University, The First Affiliated Hospital of Anhui Medical University, Shanghai East Hospital of Tongji University, Changshu Affiliated Hospital of Soochow University, Qinghai People's Hospital, The Second People's Hospital of Baoshan, Yunnan Province, Lanzhou University Second Hospital, The Affiliated Hospital of Inner Mongolia Medical University, The First People's Hospital of Nantong
Conditions Gallbladder Carcinoma
Enrollment 102 participants
Start Date 2020-06-01
Primary Completion 2025-06 (estimated)
Study Completion 2025-12 (estimated)
Updated on ClinicalTrials.gov 2024-10-16